Structure-based drug design targeting the cell membrane receptor GPBAR1: Exploiting the bile acid scaffold towards selective agonism

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Di Leva, Francesco Saverio ^a   Festa, Carmen ^a   Renga, Barbara ^b   Sepe, Valentina ^a   Novellino, Ettore ^a   Fiorucci, Stefano ^b   Zampella, Angela ^a   Limongelli, Vittorio ^a,c  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b Dipartimento di Medicina Clinica e Sperimentale Nuova Facoltà di Medicina   (Italy)

^c UNIVERSITY OF LUGANO   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

G PROTEIN COUPLED RECEPTOR; GPBAR1 PROTEIN, HUMAN; LITHOCHOLIC ACID; PROTEIN BINDING;

AGONISTS; ANALOGS AND DERIVATIVES; BINDING SITE; CHEMISTRY; DOSE RESPONSE; DRUG DESIGN; DRUG EFFECTS; GENE EXPRESSION; HEK293 CELL LINE; HEP-G2 CELL LINE; HUMAN; METABOLISM; MOLECULAR DOCKING; MOLECULARLY TARGETED THERAPY; SYNTHESIS; TRANSCRIPTION INITIATION;

BINDING SITES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; GENE EXPRESSION; HEK293 CELLS; HEP G2 CELLS; HUMANS; LITHOCHOLIC ACID; MOLECULAR DOCKING SIMULATION; MOLECULAR TARGETED THERAPY; PROTEIN BINDING; RECEPTORS, G-PROTEIN-COUPLED; TRANSCRIPTIONAL ACTIVATION;

EID: 84947093527     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep16605     Document Type: Article

References (25)

1. Kuipers, F., Bloks, V. W. & Groen, A. K. Beyond intestina soap-bile acids in metabolic control Nat. Rev. Endocrinol. 10, 488-498 (2014).
2. Fiorucci, S., Mencarelli, A., Palladino, G. & Cipriani, S. Bile-acid-activated receptors: targeting TGR5 and farnesoid-X-receptor in lipid and glucose disorders. Trends Pharmacol. Sci. 30, 570-580 (2009).
3. Forman, B. M. et al. Identification of a nuclear receptor that is activated by farnesol metabolites. Cell 81, 687-693 (1995).
4. Seol, W., Choi, H. S. & Moore, D. D. Isolation of proteins that interact specifically with the retinoid X receptor: two novel orphan receptors. Mol. Endocrinol. 9, 72-85 (1995).
5. Fiorucci, S., Mencarelli, A., Distrutti, E., Palladino, G. & Cipriani, S. Targeting farnesoid-X-receptor: from medicinal chemistry to disease treatment. Curr. Med. Chem. 17, 139-159 (2010).
6. Schaap, F. G., Trauner, M. & Jansen, P. L. Bile acid receptors as targets for drug development. Nat. Rev. Gastroenterol. Hepatol. 11, 55-67 (2014).
7. Maruyama, T. et al. Identification of membrane-type receptor for bile acids (M-BAR). Biochem. Biophys. Res. Commun. 298, 714-719 (2002).
8. Kawamata, Y. et al. A G protein-coupled receptor responsive to bile acids. J. Biol. Chem. 278, 9435-9440 (2003).
9. Watanabe, M. et al. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature 439, 484-489 (2006).
10. Thomas, C. et al. TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metab. 10, 167-177 (2009).
11. Parker, H. E. et al. Molecular mechanisms underlying bile acid-stimulated glucagon-like peptide-1 secretion. Br. J. Pharmacol. 165, 414-423 (2012).
12. Fiorucci, S., Cipriani, S., Baldelli, F. & Mencarelli, A. Bile acid- activated receptors in the treatment of dyslipidemia and related disorders. Prog. Lipid Res. 49, 171-185 (2010).
13. Tiwari, A. & Maiti, P. TGR5: an emerging bile acid G-protein-coupled receptor target for the potential treatment of metabolic disorders. Drug Discovery Today 14, 523-530 (2009).
14. Rizzo, G. et al. Functional characterization of the semisynthetic bile acid derivative INT-767, a dual farnesoid X receptor and TGR5 agonist. Mol. Pharmacol. 78, 617-630 (2010).
15. D'Amore, C. et al. Design, synthesis, and biological evaluation of potent dual agonists of nuclear and membrane bile acid receptors. J. Med. Chem. 57, 937-954 (2014).
16. Alemi, F. et al. The TGR5 receptor mediates bile acid-induced itch and analgesia. J. Clin. Invest. 123, 1513-1530 (2013).
17. Pellicciari, R. et al. 6-α-Ethyl- chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. J. Med. Chem. 45, 3569-3572 (2002).
18. Pellicciari, R. et al. Discovery of 6α-ethyl-23(S)-methylcholic acid (S-EMCA, INT-777) as a potent and selective agonist for the TGR5 receptor, a novel target for diabesity. J. Med. Chem. 52, 7958-7961 (2009).
19. Festa, C. et al. Exploitation of cholane scaffold for the discovery of potent and selective farnesoid X receptor (FXR) and G-protein coupled bile acid receptor 1 (GP-BAR1) ligands. J. Med. Chem. 57, 8477-8495 (2014).
20. Mi, L. Z. et al. Structural basis for bile acid binding and activation of the nuclear receptor FXR. Mol Cell. 11, 1093-1100 (2003).
21. Macchiarulo, A. et al. Probing the binding site of bile acids in TGR5. ACS Med. Chem. Lett. 4, 1158-1162 (2013).
22. Sepe, V. et al. Modification on ursodeoxycholic acid (UDCA) scaffold. Discovery of bile acid derivatives as selective agonists of cell-surface G-protein coupled bile acid receptor 1 (GP-BAR1). J. Med. Chem. 57, 7687-7701 (2014).
23. Glide, version 6.7, Schrödinger, LLC, New York, NY (2015).
24. Morris, G. M. et al. J. Autodock4 and AutoDockTools4: automated docking with selective receptor flexiblity. J. Comput. Chem. 16, 2785-2791 (2009).
25. Huey, R., Morris, G. M., Olson, A. J. & Goodsell, D. S. A Semiempirical Free Energy Force Field with Charge-Based Desolvation. J. Comput. Chem. 28, 1145-1152 (2007).